- Home
- GLSI vs ACHV Comparison
GLSI vs ACHV Comparison
Compare GLSI & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- ACHV
- Stock Information
- Founded
- GLSI 2006
- ACHV N/A
- Country
- GLSI United States
- ACHV United States
- Employees
- GLSI N/A
- ACHV N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GLSI Health Care
- ACHV Health Care
- Exchange
- GLSI Nasdaq
- ACHV Nasdaq
- Market Cap
- GLSI 145.2M
- ACHV 167.6M
- IPO Year
- GLSI 2020
- ACHV N/A
- Fundamental
- Price
- GLSI $8.66
- ACHV $4.59
- Analyst Decision
- GLSI Strong Buy
- ACHV Strong Buy
- Analyst Count
- GLSI 1
- ACHV 1
- Target Price
- GLSI $39.00
- ACHV $12.00
- AVG Volume (30 Days)
- GLSI 81.6K
- ACHV 2.4M
- Earning Date
- GLSI 11-14-2025
- ACHV 11-06-2025
- Dividend Yield
- GLSI N/A
- ACHV N/A
- EPS Growth
- GLSI N/A
- ACHV N/A
- EPS
- GLSI N/A
- ACHV N/A
- Revenue
- GLSI N/A
- ACHV N/A
- Revenue This Year
- GLSI N/A
- ACHV N/A
- Revenue Next Year
- GLSI N/A
- ACHV N/A
- P/E Ratio
- GLSI N/A
- ACHV N/A
- Revenue Growth
- GLSI N/A
- ACHV N/A
- 52 Week Low
- GLSI $7.88
- ACHV $1.84
- 52 Week High
- GLSI $15.47
- ACHV $5.78
- Technical
- Relative Strength Index (RSI)
- GLSI 38.48
- ACHV 55.42
- Support Level
- GLSI $8.02
- ACHV $4.77
- Resistance Level
- GLSI $9.51
- ACHV $5.42
- Average True Range (ATR)
- GLSI 0.57
- ACHV 0.39
- MACD
- GLSI -0.06
- ACHV -0.07
- Stochastic Oscillator
- GLSI 31.88
- ACHV 21.18
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.